Abstract P5-03-07: Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes
Authors: Giridhar Karthik V , Choong Grace M , Yadav Siddartha , Polley Eric C , Leon-Ferre Roberto A , Liu Minetta C , Goetz Matthew P , Couch Fergus J 
Published: March 2020

Background: BRCA1/2 carriers have higher scores in the 21-gene RS assay compared to non-carriers. Little is known about the 21-gene RS patterns in women harboring germline mutations in genes outside BRCA1/2.

Methods: We utilized the Mayo Clinic Breast Cancer Study Registry to identify individuals with non-metastatic estrogen receptor positive breast cancer and clinical 21-gene RS results available. We cross-referenced this with an institutional registry of patients tested for hereditary cancer genes, either from the electronic health record or from a research study conducted using a custom QIAseq multiplex amplicon-based panel (Qiagen). The latter assay covered target regions of all coding regions for the following predisposition genes: ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, ERCC2, FANCC, FANCM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, PRSS1, STK11, TP53, and XRCC2. Student’s t-test was used to compare 21-gene RS between carriers, non-carriers, and specific carrier genes (JMP v 14.0).

Results: 282 patients were identified with early stage breast cancer and 21-gene RS available, including 85 known mutation carriers and 197 non-carriers (or unknown carrier status). Germline mutations were identified in CHEK2 (n=25), BRCA2 (n=18), ATM (n=10), BRCA1 (n=5), PALB2 (n=5), TP53 (n=3), FANCM (n=2), MUTYH (n=2), PMS2 (n=2), PPM1D (n=2), RECQL (n=2), BARD1 (n=1), BLM (n=1), CDH1 (n=1), ERCC2 (n=1), FANCC (n=1), MSH6 (n=1), NBN (n=1), PRSS1 (n=1), and PTEN (n=1). In the entire cohort, the mean 21-gene RS was 20.4 in carriers and 18.0 in non-carriers (p=0.11). We performed individual analyses on specific genes identified in ≥ 5 patients (table 1). Compared to the mean RS in non-carriers (18.0), higher mean RS were observed in patients harboring BRCA1 (38.8, p=0.002), PALB2 (26.6, p=0.0724), and BRCA2 (23.2, p=0.0453). The RS in CHEK2 and ATM carriers were comparable to those of non-carriers.

Conclusions: We observed differences in RS score distribution based on specific mutated breast cancer predisposition genes. Further validation of the distribution and performance of the 21-gene RS in germline carriers is needed.

21-gene RS scorenMedian RSMean≤1516-25≥26n%n%n%CHEK2251616.61248728624BRCA2182123.2211.11161.1527.8ATM101716.9330550220BRCA153635.8120120360PALB253326.6120120360None1971518.09950.367343115.7

Citation Format: Karthik V Giridhar, Grace M Choong, Siddartha Yadav, Eric C Polley, Roberto A Leon-Ferre, Minetta C Liu, Matthew P Goetz, Fergus J Couch. Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-03-07.